Clinical trial

A Multicenter, Real-world Study of the Efficacy and Safety of Antibody-drug Conjugates (ADCs) Rechallenge in Patients With Prior Exposure to ADCs Metastatic Breast Cancer

NCT05571618

Name

YOUNGBC-23

Description

To investigate the efficacy and safety of ADC rechallenge

Trial arms

Trial start

2022-09-01

Estimated PCD

2024-09-01

Trial end

2024-09-01

Status

Active (not recruiting)

Treatment

ADC

Patients with prior exposure to ADC (either in the adjuvant setting or metastatic disease are allowed).

Arms:

Group1

Size

100

Primary endpoint

PFS

6 weeks

Eligibility criteria

Inclusion Criteria: * age \> 18 years old. * Diagnosed with Metastatic Breast Cancer. * Patients with prior exposure to ADC (either in the adjuvant setting or metastatic disease are allowed). * Patients plan to or have received ADCs for the second or more time. * Complete medical history was available. Exclusion Criteria: * Medical history was incomplete

Protocol

{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}}

Updated at

2024-02-26

1 organization

1 drug

1 indication

Organization

Fudan University

Drug

ADC

Indication

Breast Cancer